ISPC earnings analysis
What we found in ISPC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q sections do not include the income statement, balance sheet, cash flow statement, or segment tables, so current-quarter revenue, margins, EPS, cash flow, and working-capital metrics are unavailable. The filing nevertheless reports an unresolved material weakness as of June 30, 2026, an approximately 83% six-month revenue decline, and a 245% increase in sales and marketing expense. Management also identifies substantial doubt about the company’s ability to continue as a going concern, while legal matters include a $651,262 Azenta claim and a remaining Focus dispute.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Material weakness remains unresolved
- Management concluded disclosure controls were not effective as of June 30, 2026 because controls over customer tax-exempt documentation, sales-tax collection, and remittance were inadequate. Remediation has been ongoing since the second quarter of fiscal 2023.
- EGS litigation settled
- The company settled the EGS legal matter for $200,000 pursuant to an agreement executed February 15, 2026, reducing the uncertainty associated with that proceeding.
- Focus dispute remains a cash risk
- Focus litigation remains in discovery after the company withheld payments under a $500,000 settlement agreement; only $13,000 has been deposited into escrow under the clarified 15% net-revenue security order.
- Azenta claim has defined settlement exposure
- Management has made a $125,000 settlement offer in the Azenta case, which involves a $651,262 claim, and expects Azenta to seek summary judgment.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue contraction
- Revenue declined approximately 83% for the six months ended June 30, 2026 versus the prior-year period, indicating severe deterioration in operating scale.
- Marketing spend outpaces revenue
- Sales and marketing expenses increased approximately 245% for the six months ended June 30, 2026 versus the prior-year period, primarily due to advertising and promotion costs, while revenue continued to decline.
- Nasdaq compliance and split risk
- The company completed a second reverse stock split at a 1-for-40 ratio in April 2026 to regain or maintain compliance with Nasdaq's minimum bid-price requirement, highlighting continued listing risk and potential dilution pressure.
What they said about what is next.
The supplied 10-Q text does not provide numeric revenue or EPS guidance. Management states remediation is ongoing but cannot assure when the material weakness will be fully remediated or what additional costs may be required.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- iSpecimen's Q1 2026 results showed a significant decline in revenue to $156,009, down 85% from $1,057,510 in Q1 2025, largely due to a decrease in specimen orders. EPS worsened to -$2.28 compared to -$1.58 in the prior…
- 10-K · April 1, 2026
- iSpecimen positions itself as an “Amazon-like” global marketplace connecting researchers to human biospecimens and associated data, recently investing in a cloud-native SalesStack re-platform to modernize its…
- 10-Q · August 14, 2025
- iSpecimen reported Q2 revenue of $713,135, down sharply from $2,863,679 in Q2 2024 and down vs. Q1 2025 ($1,057,510). Gross margin compressed to 37.7% (from 50.3% in 2024Q2) while operating loss widened to -$1.82M…
- 10-Q · May 19, 2025
- iSpecimen reported Q1 revenue of $1,057,510, down $1,232,483 (‑53.8%) from $2,289,993 a year ago, and a net loss of $1,658,396 (EPS $(0.71)) versus a loss of $2,902,117 (EPS $(6.36)) in Q1 2024. Gross margin narrowed to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ISPC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever